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Selective internal radiation therapy (SIRT) is a promising treatment modality for advanced
hepatocellular carcinoma or metastatic liver cancer. SIRT is usually well tolerated. However,
in most patients, SIRT will result in a (temporary) decreased liver function. Occasionally
patients develop radioembolization-induced liver disease (REILD). In case of a high tumor
burden of the liver, it could be beneficial to perform SIRT in two sessions enabling the
primary untreated liver segments to guarantee liver function until function in the treated
segments has recovered or functional hypertrophy has occurred. Clinically used liver func-
tion tests provide evidence of only one of the many liver functions, though all of them lack
the possibility of assessment of segmental (regional) liver function. Hepatobiliary scintig-
raphy (HBS) has been validated as a tool to assess total and regional liver function in
liver surgery. It is also used to assess segmental liver function before and after portal
vein embolization. HBS is considered as a valuable quantitative liver function test enabling
assessment of segmental liver function recovery after regional intervention and determi-
nation of future remnant liver function. We present two cases in which HBS was used
to monitor total and regional liver function in a patient after repeated whole liver SIRT
complicated with REILD and a patient treated unilaterally without complications.
Keywords: radionuclide imaging, hepatobiliary imaging, SPECT/CT, hepatocellular carcinoma, liver function,
selective internal radiation therapy
INTRODUCTION
Radioembolization (also called selective internal radiation ther-
apy or SIRT) is a form of brachytherapy in which intra-arterially
injected 90 Y-loaded microspheres serve as sources for internal
radiation purposes of non-resectable liver tumors. Average dis-
ease control ranges from 70 to 90% or even higher and SIRT
is usually very well tolerated (1–3). Patients considered candi-
dates for SIRT are patients with liver malignancies who do not
qualify for surgical resection, radio frequent ablation, or transar-
terial chemoembolization. Most of these patients are classified as
intermediate or advanced disease stage according to the Barcelona
Clinic Liver Cancer scheme (4).
Severe side-effects of SIRT are not common after radioem-
bolization. Several rather mild procedure-related symptoms may
ensue including fatigue (54–61%), abdominal pain (23–56%),
nausea and vomiting (20–32%), and low-grade fever (3–12%) that
usually last only a few hours (5). Radioembolization appears to
be well-tolerated and effective for the elderly as it is for younger
patients with unresectable hepatocellular carcinoma (HCC) (6).
Mild-to-moderate lymphopenia is commonly seen after radioem-
bolization but not associated with increased susceptibility to infec-
tions (5). Main liver function related complications do not result
from the microembolic effect of SIRT, even in patients with por-
tal vein occlusion, but rather from an excessive irradiation of
non-target liver tissue.
In a cirrhotic liver, the effect of radioembolization can affect
the liver in two ways. On one hand, the usual distribution of
microspheres can be profoundly altered by the vascular changes
that occur in the cirrhotic liver. This altered microvascular pattern
and the presence of anatomical arterio-portal and arterio-venous
shunts may modify the radiation dose absorbed by the tumor
and the non-tumoral liver and therefore affect treatment toler-
ance and effectiveness. On the other hand, the cirrhotic liver has
a reduced functional reserve which increases the risk of liver fail-
ure after major liver surgery, liver insults including toxic or viral
acute hepatitis and external irradiation. A direct liver cell injury
and a further compromise of liver blood supply produced by
radiation-mediated blood vessel damage could result in a higher
risk of clinically relevant liver toxicity after radioembolization in
comparison with non-cirrhotic livers (5).
RADIOEMBOLIZATION-INDUCED LIVER DISEASE
Irradiation of the non-tumor liver tissue can result in an
uncommon but potentially life-threatening condition after SIRT:
radioembolization-induced liver disease (REILD). REILD has
been recently distinguished from other liver toxicity diseases,
such as radiation-induced liver disease (RILD) which is seen
after external beam radiation, by the research group of Bilbao
et al. (7). REILD is defined as a syndrome appearing 4–8 weeks
after radioembolization as jaundice, mild ascites, and a moderate
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increase in GGT and alkaline phosphatize. It differs from RILD
in the association with young age and the treatment intensity. It
is seen in patients with liver cirrhosis or in patients who under-
went chemotherapy prior or subsequent to SIRT (8). Recently,
a modified treatment protocol with the aim to reduce the fre-
quency and severity of REILD was presented by the same research
group. In the modified protocol, the authors describe adjustments
in the activity calculation together with the use of ursodeoxycholic
acid and steroid therapy leading to a reduction in the frequency
and severity of REILD. Although the study describes the largest
cohort after SIRT so far, it lacks histopathological evidence. With-
out histopathological evidence, it is impossible to prove whether
the clinical symptoms in cirrhotic patients are related to REILD
or to progression of cirrhosis. Furthermore, the modified proto-
col implies lowering of the treatment activity. Though a decrease
in treatment efficacy is not reported, we consider the evidence
too little to introduce this new modified protocol in our daily
practice.
LIVER FUNCTION
In clinical practice, we assume that SIRT will probably result
in a (temporary) decreased liver function or occasional REILD.
To minimize this risk, one can perform SIRT in two sessions
enabling the primary untreated liver segments to guarantee liver
function until function in the treated segments has recovered. At
this moment, changes in the regional liver function after SIRT
are unknown. The timing of the second SIRT-session is cru-
cial as, if performed too early (i.e., before the function in the
treated segments has recovered or the function in the non-treated
lobes has compensated), it may cause the same complications as
when performed in one session. In order to improve the current
SIRT strategy, we need to investigate the changes in regional liver
function after SIRT.
The liver is responsible for a spectrum of functions includ-
ing the uptake, metabolism, conjugation, and excretion of various
endogenous and foreign substances. Most of the different func-
tions of the liver are performed by hepatocytes but to a smaller
degree by other liver cells. The substrates, by-products, or final
products of those processes can be used to estimate liver function.
However, few of the tests used in everyday clinical practice truly
measure liver function. They rather provide an indirect evidence
of only one of the liver’s many processes.
Categorization schemes are based either on laboratory findings
entirely or the combination of laboratory and clinical findings. The
approach is to either stratify patients into groups with increasing
degree of dysfunction or to calculate a score that reflects sever-
ity of liver dysfunction. The most widely used system today in
adults is the model for end-stage liver disease (MELD) scoring
system that uses the International Normalized Ratio (INR) in
combination with serum bilirubin and serum creatinin values to
predict survival (9). Another widely used scoring system is the
Child–Pugh–Turcotte (CPT) score which includes total bilirubin
serum level, albumin serum level, and prothrombin time together
with the presence or absence of encephalopathy and ascites. The
CPT scoring system categorizes patients into three groups (termed
Child A, B, and C – in the order of increasing dysfunction) and
is particularly useful in selecting patients with HCC and cirrhosis
for resection or transplantation. Patients with liver metastases,
who usually have normal liver parenchyma and who are classified
as class Child A, are considered as candidates for liver resection.
Detection of patients at risk for postoperative liver failure is of
great importance. In these patients, the CPT score has been shown
to be quite variable and may be unreliable for predicting the out-
come of liver resections, especially in patients with non-cirrhotic
livers (9).
The indocyanine green (ICG) clearance test was initially
devised for the measurement of blood flow and later found clin-
ical application in the assessment of liver function by yielding a
measurement of functional hepatocyte mass. It is now the most
widely used quantitative liver function test in clinical use in the
setting of liver surgery. ICG is exclusively removed by the liver and
excreted into the bile without intrahepatic conjugation. Elimina-
tion is dependent on hepatic blood flow,cellular uptake,and biliary
excretion. The disappearance of ICG from the blood reflects the
liver’s capacity to transport organic anions and metabolize drugs
providing an indirect measurement of global liver function. A lim-
itation is that ICG clearance test reflects global liver function, but
it does not take into account regional variations in liver quality
that may occur (10).
HEPATOBILIAR SCINTIGRAPHY
Another frequently used quantitative liver function test is 99mTc-
mebrofenin hepatobiliary scintigraphy (HBS). 99mTc-mebrofenin
is a hepatic specific lidocaine analog and is transported to the liver
bound to albumin and dissociates from albumin in the hepatic
space of Disse from where it is taken up by the hepatocytes. Sub-
sequently, mebrofenin is excreted into the bile canaliculi without
prior biotransformation. The hepatic uptake represents one of the
main hepatic processes and the use of 99mTc-mebrofenin HBS for
preoperative assessment of liver function in patients undergoing
liver surgery was first described by Erdogan et al. In 54 patients
scheduled for liver resection, the Mebrofenin uptake rate (MUR)
strongly correlated with the ICG clearance test (11). HBS can be
used in patients with normal and compromised liver parenchyma
as the test is validated with a single cut-off value (2.69%/min/m2)
for both categories of patients (12). Underlying liver disease is
often unknown and remains unknown until liver resection is per-
formed, if applicable. Liver biopsies are not taken routinely as
the distribution of compromised parenchyma in the liver is not
homogeneous leading to sampling errors and because of the risk
of biopsy related complications. This is one of the main advantages
of HBS compared to other modalities and increases its applicabil-
ity in daily practice especially in patients with an uncertain quality
of liver parenchyma.
Besides quantitative information, HBS provides visual infor-
mation about the localization of liver segments with poor func-
tion. Because of the possibility of determining regional liver func-
tion, HBS was validated as a preoperative method for estimating
future remnant liver (FRL) function. In this relatively small patient
study, preoperatively estimated FRL function correlated well with
actual remnant liver function 1 day after resection (10). A recent
study including 36 patients demonstrated that 99mTc-mebrofenin
SPECT combined with subsequent low dose CT provided valu-
able visual information on the distribution of liver function (12).
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The results of functional liver volume measured by SPECT and
morphologic volume measured by CT volumetry indicated that
SPECT was an accurate method of measuring hepatic volume.
FRL (corrected) cMUR measured by the combination of SPECT
and dynamic HBS was able to accurately predict the actual func-
tion of the postoperative remnant liver. Preoperative portal vein
embolization (PVE) is often performed in patients with insuf-
ficient FRL volume in order to achieve resectability. It induces
atrophy of the embolized, tumor-bearing liver segments, while
compensatory hypertrophy occurs in the non-embolized liver,
thereby increasing FRL volume and function. PVE reduces the risk
of postoperative liver insufficiency and enables resection of livers
previously considered unresectable because of marginal FRL. Few
studies have investigated the improvement in FRL function after
PVE, since most quantitative liver function tests lack the abil-
ity to measure FRL function selectively. In a study by de Graaf
et al., it was confirmed that the increase in FRL function was
more pronounced than the increase in FRL volume after PVE (13).
The uptake function in the FRL per liter of liver tissue increases
after PVE. The increased liver function per gram or milliliter of
liver tissue has been described previously during liver regeneration
after partial hepatectomy. Combination of the ICG clearance test
and the percentage of FRL volume derived by CT volumetry has
FIGURE 1 | A 65-year-old male patient with multifocal recurrent
hepatocellular carcinoma (HCC) 6months after resection of a HCC in
liver segment 7–8. (A,B) Arterial phase contrast-enhanced CT showing
operation clips in situ after resection of the primary HCC and multiple sites
of contrast enhancement (with wash-out on delayed images – not shown).
(C)Yttrium-90 PET-lowdose CT and (D) maximum intensity projection after
treatment with 1.7 GBq 90 Y labeled SIR-Spheres, showing markedly
increased uptake of SIR-Spheres at the site of resection and multifocal in
both right and left liver lobes, with clear right-sided predominancy.
(E,F) Arterial phase contrast-enhanced CT showing response with central
necrosis in tumor lesions, with no significant changes in liver volume.
been described for the assessment of FRL function after PVE. This
method, however, is based on the assumption that the increase in
FRL volume is related to the increase in FRL function, and that
liver function is distributed homogeneously within the liver vol-
ume. However, only a weak correlation between the increase in
FRL volume and FRL function was found, and so combination of
the ICG clearance test with the percentage FRL volume derived
from CT volumetry may not accurately measure FRL function
after PVE. This indicates the importance of additional quanti-
tative functional assays that specifically measure FRL function
after PVE.
For liver surgery, HBS has been validated as a tool to assess
total and regional liver function, and is performed routinely in our
patients before major liver resection (14). It is also used to assess
segmental liver function before and after PVE. HBS is considered
as a valuable quantitative liver function test enabling assessment of
segmental liver function recovery after regional intervention and
determination of FRL function.
FIGURE 2 | Hepatobiliary scintigraphy before (A) and 6weeks after (B)
whole liver treatment with 1.7GBq 90Y labeled SIR-Spheres in a
65-year-old male patient with multifocal predominantly right-sided
recurrent hepatocellular carcinoma (Figure 1). Displayed are summed
dynamic frames (2×10 s/frame), a summed image (20×10 s) with regions
of interest drawn around the entire liver (red), left liver segments 2–4 (blue),
and cardiac blood pool (yellow), and corresponding time–activity curves. The
total liver function (body surface area corrected mebrofenin uptake rate)
was reduced after treatment from 7.4 to 6.1%/min (red curves). However,
function of left liver lobes 2–4 increased from 3.4 to 4.1%/min (blue). This
functional increase is both relative and absolute and can be explained by
insufficient post treatment functional liver capacity leading to functional
hypertrophy in non-affected liver segments.
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In this light, we consider 99mTc-mebrofenin HBS a suitable
quantitative liver function test to monitor regional liver function
changes after SIRT. The effect of SIRT observed 4–6 weeks after
the procedure is performed. HBS is performed before and 6 weeks
after SIRT in order to measure the changes in the treated and
non-treated lobes. If our hypothesis is correct and SIRT does
cause decrease in liver function in the treated segments and
(hyper)function in the untreated segments, HBS can be used as
a monitoring tool in order to determine the timing of the second
SIRT session.
CASE EXAMPLES
The two case examples presented here illustrate the possible role
of total and regional functional imaging of the liver. Both patients
were treated with SIR-Spheres for HCC in a salvage setting. Imme-
diately before and 6 weeks after the SIRT, liver function was
measured with HBS as described elsewhere (11).
It is shown that HBS is able to depict relative and absolute
change in regional liver function in non-affected liver segments.
FIGURE 3 | Hepatobiliary scintigraphy before (A) and 6weeks after (B)
a second treatment (6-month interval) with 1.5GBq 90Y labeled
SIR-Spheres in a 65-year-old male patient with multifocal
predominantly right-sided recurrent hepatocellular carcinoma
(Figure 1). Displayed are summed dynamic frames (2×10 s/frame), a
summed image (20×10 s) with regions of interest drawn around the entire
liver (red), left liver segments 2–4 (blue), and cardiac blood pool (yellow),
and corresponding time–activity curves. The total liver function (body
surface area corrected mebrofenin uptake rate) was reduced after
treatment from 4.8 to 2.2%/min (red curves). This time, function of left liver
lobes 2–4 decreased proportionally from 3.2 to 1.6%/min (blue). The patient
was diagnosed with radiation embolization induced liver disease.
Case 1: Multifocal HCC, SIRT whole liver treatment twice
(Figures 1–3).
Case 2: Multifocal HCC, SIRT right-sided liver segments
(Figure 4).
CONCLUDING REMARKS
Hepatobiliary scintigraphy is able to give insight into relative liver
function before SIRT and depict relative and absolute change in
regional liver function in non-affected liver segments after SIRT.
This could be of importance in risk stratification of patients before
the first treatment or timing of subsequent treatment.
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FIGURE 4 | Hepatobiliary scintigraphy before (A) and 6weeks after (B)
right-sided treatment with 1.8GBq 90Y labeled SIR-Spheres in a
64-year-old male patient with multifocal exclusively right-sided
hepatocellular carcinoma with portal vein invasion. Displayed are
summed dynamic frames (2×10 s/frame), a summed image (20×10 s)
with regions of interest drawn around the entire liver (red), left liver
segments 2–4 (blue), and cardiac blood pool (yellow), and corresponding
time–activity curves. The total liver function (body surface area corrected
mebrofenin uptake rate) was reduced after treatment from 8.5 to 6.9%/min
(red curves). However, function of left liver lobes 2–4 remained unchanged
4.8%/min (blue). This functional increase is only relative and can be
explained by lack of functional hypertrophy in the presence of sufficient
post treatment functional liver capacity.
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